2ND INTERNATIONAL MULTIDISCIPLINARY CONSENSUS ON THE INTEGRATION OF RADIATION THERAPY WITH NEW SYSTEMIC TREATMENTS

INTRODUCTION
This consensus project, scheduled for Friday-Saturday 9-10 October 2026, is conceived
as a high-level scientific educational event dedicated to multidisciplinary updates on the
most recent innovations in the treatment of major high-incidence solid tumours: head and
neck, prostate, kidney and breast cancer.
The evolution of modern oncology is characterised by an increasing integration between
innovative systemic therapies (immunotherapy, targeted therapies, antibody-drug
conjugates, PARP inhibitors) and precision radiation therapy, with a significant impact on
clinical outcomes, patients’ quality of life, and the sustainability of care pathways. In this
context, it is essential for healthcare professionals to acquire up-to-date knowledge not
only on individual therapeutic strategies, but above all on their rational and sequential
integration.
The scientific programme is structured around keynote lectures delivered by internationally
recognised experts, addressing:
• the role of the tumour micro-environment and the biological mechanisms underlying
response and resistance to therapies;
• the transformative impact of immunotherapy in head and neck tumours and breast
cancer;
• the evolution of systemic strategies in genitourinary tumours, with particular attention
to metastatic disease;
• technological and clinical advances in radiation therapy, and how to translate technical
innovation into tangible clinical benefit;
• new perspectives in clinical trial design and therapeutic sequencing, particularly in
advanced breast cancer;
• the growing role of patient engagement and advocacy in oncological care pathways.
The event addresses concrete and current educational needs of healthcare professionals,
promoting:
• evidence-based updates on emerging therapeutic options;
• multidisciplinary discussion among medical oncologists, radiation oncologists,
surgeons and other specialists;
• enhanced decision-making skills in daily clinical practice, aligned with the most recent
scientific evidence and international guidelines.
In light of the increasing complexity of oncological treatments and the rapid evolution of
knowledge, the congress represents an essential educational opportunity to ensure
clinical appropriateness, treatment safety and continuous improvement in the
quality of care.
CO-PRESIDENTS
Lorenzo Livi
Icro Meattini
Pierluigi Bonomo
Giulio Francolini